menu
    • menu
    [{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Clazosentan Sodium","moa":"Endothelin A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clazosentan Sodium","moa":"Endothelin A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clazosentan Sodium","moa":"ET receptor","graph1":"Neurology","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clazosentan Sodium","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Clazosentan Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Sosei Heptares","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Pharmaceuticals \/ Sosei Heptares"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clazosentan Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Group Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"HANDOK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Clazosentan Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sosei Group Corporation \/ Handok","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Group Corporation \/ Handok"}]

    Find Clinical Drug Pipeline Developments & Deals for Clazosentan Sodium

    Menu

    Clazosentan Sodium

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sosei Group Corporation

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sosei Group Corporation

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : HANDOK

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nxera Pharma Announces Exclusive Supply Agreement with Handok for Pivlaz™

                            Details : Handok is responsible for commercialization of Pivlaz (clazosentan sodium), approved in South Korea for preventing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.

                            Brand Name : Pivlaz

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 14, 2024

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : HANDOK

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sosei Group Corporation

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sosei Group Corporation

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea

                            Details : South Korea approved PIVLAZ™ (clazosentan sodium), an ETAR antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.

                            Brand Name : Pivlaz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 07, 2023

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Sosei Heptares

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Tr...

                            Details : Through the acquisition, Sosei also gains assignment of Pivlaz (clazosentan), for the treatment of cerebral vasospasm, and license rights to daridorexant in the Asia Pacific (ex-China) region.

                            Brand Name : Pivlaz

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 20, 2023

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Sosei Heptares

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Idorsia Announces the Results Of REACT a Phase 3 Study of Clazosentan in Patients Following Aneurysmal Subarac...

                            Details : ACT-108475 (clazosentan) is a fast-acting, endothelin A (ETA) receptor antagonist, that Idorsia has developed as a continuous intravenous infusion for the prevention of clinical deterioration due to delayed cerebral ischemia (DCI) in patients following a...

                            Brand Name : ACT-108475

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 06, 2023

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Idorsia Receives Japanese PMDA Approval of PIVLAZ (clazosentan sodium) 150 mg

                            Details : PIVLAZ (clazosentan sodium), a selective endothelin A receptor antagonist received Japanese PMDA approval on the basis of statistically significant result from the Japanese Phase 3 program for the prevention of cerebral vasospasm after subarachnoid hemor...

                            Brand Name : Pivlaz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 20, 2022

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Idorsia Submits NDA for Clazosentan to Japanese PMDA

                            Details : A Phase 2 study in Japanese and Korean patients showed that 10 mg/hr of clazosentan administered by continuous intravenous infusion significantly reduced vasospasm and vasospasm-related morbidity and mortality events.

                            Brand Name : ACT-108475

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2021

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Idorsia Announces Positive Results of the Two Japanese Registration Studies with Clazosentan

                            Details : Both studies demonstrated that clazosentan reduced the occurrence of cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH with statistical significance (p<0.01 for both studies).

                            Brand Name : ACT-108475

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 23, 2020

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth